There were a bunch of biotech stocks making huge breakout moves today, one on a buyout, s few more on drug tests, and
ACHN, which is a combination of the two. It did have a successful drug test but, according to the reports I read, is strongly suspected of being a buyout target. Notice how it came right up to the target projected for it by the previous two pivot points: I suspect it's not going to go much higher than that.
